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CONCLUSION: The CRISPR/Cas9 method targeted to a 
highly conserved sequence of fgfr1a introduced a diverse 
array of mutagenized alleles providing the opportunity 
to investigate suture development in correlation with 
new pathologic alleles. These mutations are heritable and 
despite the high sequence homology among genes encod-
ing Fgf receptors, no off-target mutations have been identi-
fied to date. Initial characterization of identified alleles will 
focus on embryonic stages to assess the effect of mutation 
on Fgf signaling target genes. This analysis will be comple-
mented by histology of zebrafish head to assess the cranial 
suture development and maintenance of juvenile and adult 
animals.
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PURPOSE: Our aim was to identify patient characteristics 
and procedures associated with bleeding complications dur-
ing plastic surgery.
METHODS: The American College of Surgeons National 
Surgical Quality Improvement Program (NSQIP) database 
was queried to identify all primary plastic surgery proce-
dures from 2008 to 2013. Patients with bleeding complica-
tions as defined by NSQIP were identified. Patients who had 
a documented bleeding disorder were separately identified. 
Procedure CPT Codes, patient characteristics, and surgical 
outcomes were abstracted and analyzed to determine those 
procedures and conditions associated with bleeding com-
plications. An analysis of co-morbidities, peri-operative 
characteristics, and post-operative complications between 
bleeding and non-bleeding cohorts was performed using a 
non-paired, 2-tailed t-test and a chi-squared test with Yates 
correction.
RESULTS: Of 59,184 cases identified, 1261 (2.1%) 
experienced bleeding complications. Regarding co-mor-
bid conditions, 18.2% of patients had diabetes, 41.8% 
had hypertension, and 6.7% had bleeding disorders in the 
bleeding group compared with 7.4%, 25.9%, and 1.5% 
in the group without bleeding complications (p<0.0001). 
The most common primary procedures associated with 
bleeding complications were breast reconstruction 
with a free flap (20.7%) and myocutaneous trunk flaps 
(13.1%). The most common concurrent procedures 
associated with bleeding complications were breast 
oncology procedures (35.3%) and enterolysis (1.9%). 
The most common non-bleeding complication was dif-
ficulty weaning the patient off the ventilator. Twenty-
five patients (2.0%) with bleeding complications died 
within 30 days of the procedure. Of the primary plastic 
surgery procedures identified, 953 (1.6%) patients car-
ried a pre-existing diagnosis of bleeding disorder. The 
two most common primary procedures performed in 
this group were myocutaneous trunk flaps and reduc-
tion mammaplasty. The rate of bleeding complications 
in the group with a pre-existing bleeding disorder was 
more than four times the rate of bleeding complications 
for those without a bleeding disorder (8.9% vs. 2.0%, 
p<0.01). In addition, the rate of other non-bleeding com-
plications was significantly higher in the cohort with a 
bleeding condition (1.29% vs. 0.35%; p<0.01). The most 
common non-bleeding complications in this cohort were 
prolonged ventilation requirement (2.9%) and septic 
shock (2.9%).
CONCLUSIONS: Plastic surgery procedures have an 
overall low rate of post-op bleeding (2.1%). Bleeding 
most commonly occurs with flap reconstruction, specifi-
cally breast and trunk flaps. A pre-operative diagnosis of 
hypertension, diabetes, or bleeding disorder was associ-
ated with increased incidence of post-operative bleeding 
complications. Two percent of patients undergoing plastic 
surgery procedures during our period of study had known 
pre-operative bleeding disorders. As these patients exhibit 
a significantly higher rate of post-operative bleeding as 
well as overall post-operative complications, recogni-
tion and appropriate management pre-operatively, poten-
tially including risk stratification and a multi-disciplinary 
approach, may represent a realistic method for reducing 
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PURPOSE: More than 30,000 people receive organ trans-
plants every year in the US. Vascularized composite allo-
transplantation (VCA) is the newest realm of solid organ 
transplantation. The skin component of VCA is highly anti-
genic and mandates high doses of systemic immunosuppres-
sive drugs. Oral dosing of immunosuppressive drugs such 
as tacrolimus (TAC), rapamycin (Rapa), and mycophenolic 
acid (MPA) leads to fluctuating, erratic, or unpredictable 
blood levels risking toxicity or lack of efficacy. We propose 
a drug delivery platform that can not only provide sustained 
drug release but also on-cue triggered drug release upon 
ultrasound stimulation (USS) in graft tissues with stable, low 
blood levels, minimizing overall drug exposure and facilitat-
ing long-term VCA survival with no systemic complications.
METHOD: An injectable, re-loadable, biocompatible 
drug eluting hydrogel was prepared. We characterized the 
in vitro release kinetics of the drugs from alginate gels in 
absence and /or presence of USS. We evaluated feasibil-
ity and efficacy of the system in vivo in absence of USS. 
Brown Norway to Lewis rats received fully mismatched 
Brown Norway rat hind limb VCA (4/group) and a single 
dose of gel subcutaneously injected into the allograft. The 
gel was loaded with either TAC [10mg], Rapa [10mg], 
or TAC+Rapa [10mg] each in 1 ml. Drug levels in blood 
and VCA tissues were analyzed by LC–MS/MS. Flow 
cytometry was performed to detect expression of regula-
tory marker, FOXP3. In addition to allograft survival, sys-
temic toxicity was evaluated using percent change in body 
weight (BW) and creatinine clearance (CrCL).
RESULTS: In vitro, TAC and Rapa exhibited a low base-
line level (without fluctuation) of release from alginate 
gels in the absence of USS. Pulsatile USS triggered drug 
release, leading to increased drug levels after each pulse. 
Sustained drug release occurred from alginate gels in the 
absence of ultrasound with blood levels within the thera-
peutic range (5-10ng/ml). Drug concentration in allograft 
tissues was higher than in blood and contralateral limb 
(P<0.05). In the first 2 weeks post gel injection, there 
was a ≤15% change in BW which stabilized with time. 
BW gradually increased over time. No significant change 
in CrCL occurred post gel injection over time (>0.05). 
Rats receiving Rapa developed Banff grade 3 rejection on 
day 21, while rats receiving TAC or TAC+Rapa showed 
allograft survival (>100 days). Expression of the regula-
tory marker FOXP3 was observed which which may indi-
cate peripheral immunomodulation.
CONCLUSION: We successfully developed, for the first 
time, a smart hydrogel drug delivery system with sustained 
baseline and on-demand release of drugs upon USS for use 
in VCA. The TREAT ™ system provides stable, low drug 
levels in the blood with preferential drug concentration in 
VCA tissues facilitating long-term VCA survival/outcomes 
with no systemic adverse effects. Further efforts are being 
made to use USS to optimize the on-cue drug release.
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